The Effect of Anti-CD20 Therapies on SARS-CoV-2 Immune Responses in Multiple Sclerosis Patients

August 11, 2021

Researchers in France investigated the humoral immune response to COVID-19 in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMO-SD). Humoral immune responses use antibodies to protect against reinfection when exposed to a foreign invader.

The results of the study showed a high seroconversion rate in patients with MS and NMO-SD after COVID-19. However, patients treated with anti-CD20 therapies had a seroconversion rate twice as low as untreated patients and patients receiving a different treatment. In other words, patients treated with anti-CD20 therapies exhibited a weaker antibody response against a COVID-19 infection. Some factors found to influence seroconversion rates included IgG levels and severity of COVID-19 infection. The time between the last anti-CD20 infusion and COVID-19 was also longer in seropositive patients.

Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.